Condition

Urothelial Carcinoma clinical trials and research

• 70Clinical trials
• 16NIH research projects
• 1New in 30 days
• 29Countries

Newest Urothelial Carcinoma clinical trials

All recruiting trials (70)

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Urothelial Carcinoma Biospecimen Collection and Data Study

  This project tests collecting and storing tissue, blood, and imaging data from adults with urothelial carcinoma to support translational research.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT07789119

• DBC-664 in adults with solid tumors

  A first-in-human study will test DBC-664 to see if it is safe and tolerable in adults with various advanced solid tumors and may hint at anti-tumor activity.

  Recruiting at 7 sites Phase 1 TCG Labs Soleil · Denver, Colorado and 6 other locations · NCT07705035

• First-in-human test of HH160 in people with advanced solid tumors

  HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.

  Recruiting at 3 sites Phase 1 Huahui Health · Waratah, New South Wales and 2 other locations · NCT07623369

• BMS-986504 combined with standard treatments for certain metastatic MTAP‑deleted solid tumors

  This trial tests whether adding the experimental drug BMS‑986504 to standard cancer treatments is safe for people with advanced MTAP‑deleted mesothelioma, gastroesophageal, or urothelial cancers.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07532902

• Trastuzumab plus serplulimab with chemotherapy for HER2-positive advanced biliary tract or urothelial cancer after prior therapy

  This study will test whether adding trastuzumab and serplulimab to chemotherapy helps people with HER2-positive unresectable or metastatic biliary tract cancer or urothelial carcinoma who have not responded to standard treatment.

  Recruiting Phase 2 China Medical University, China · Shenyang, Liaoning · NCT07506057

• Dual-target Nectin-4 and HER2 CAR-NK therapy for advanced urothelial carcinoma

  This treatment will try dual-target CAR-NK cells that recognize Nectin‑4 and HER2 in adults with relapsed or metastatic urothelial carcinoma after standard therapies.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07492628

• PF-08634404 alone or with enfortumab vedotin for advanced urothelial (bladder) cancer

  This trial will try PF-08634404 by itself or together with enfortumab vedotin to see if it is safe and helps adults with advanced or metastatic urothelial (bladder) cancer.

  Recruiting at 173 sites Phase 1/2 Pfizer · Fayetteville, Arkansas and 183 other locations · NCT07421700

• GEN1106 for solid tumors, including metastatic urothelial (bladder) cancer.

  This trial tests a new drug called GEN1106 in people with metastatic solid tumors, especially urothelial (bladder) cancer, who have progressed after standard treatments.

  Recruiting at 9 sites Phase 1 Genmab · New Haven, Connecticut and 9 other locations · NCT07416123

• Hospital admissions for blood in the urine

  This international observational project will look at how hospitals manage adults admitted with blood in the urine to see which approaches lead to shorter stays and better outcomes.

  Recruiting British Urology Researchers in Surgical Training · London · NCT07395037

• Nerve effects of enfortumab vedotin in people with urothelial cancer

  We will see how nerve testing and patient-reported symptoms change in adults with urothelial cancer who are starting enfortumab vedotin.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07390617

• Sniffer dogs detecting bladder (urothelial) cancer from urine

  This study will test whether trained sniffer dogs can detect bladder cancer by smelling urine from adults scheduled for cystoscopy or other endourological procedures.

  Recruiting at 2 sites University Hospital, Strasbourg, France · Colmar and 1 other locations · NCT07334314

• Intravesical gemcitabine followed by docetaxel for high-grade BCG-unresponsive NMIBC

  This trial tests whether putting gemcitabine then docetaxel directly into the bladder can treat adults with high-grade non-muscle-invasive bladder cancer that did not respond to BCG.

  Recruiting Phase 2 University of Iowa · Iowa City, Iowa · NCT07322263

• Combining 9MW2821 with toripalimab around surgery for urothelial cancer

  This trial tests whether giving 9MW2821 together with toripalimab before and after surgery helps adults with non-metastatic urothelial cancer.

  Recruiting Phase 2 Mabwell (Shanghai) Bioscience Co., Ltd. · Guangzhou, Guangdong · NCT07314723

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

• Trastuzumab Rezetecan with or without Adebrelimab for HER2-expressing advanced urothelial cancer

  This study will test whether Trastuzumab Rezetecan alone or combined with the immunotherapy Adebrelimab helps people with HER2-expressing locally advanced or metastatic urothelial cancer.

  Recruiting at 3 sites Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 5 other locations · NCT07241793

• Ureteral stent versus no stent for adults having radical cystectomy with an ileal conduit

  This trial tests whether placing temporary ureteral stents at the time of radical cystectomy with ileal conduit reduces post-operative complications compared with not placing stents in adults having cystectomy for bladder or other pelvic cancers.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania and 1 other locations · NCT07234968

• ctDNA-guided therapy de-escalation for metastatic urothelial cancer

  This trial tests whether switching to pembrolizumab alone after 24 weeks of pembrolizumab plus enfortumab vedotin helps people with metastatic urothelial cancer who show a large drop in ctDNA.

  Recruiting Phase 2 University of Oklahoma · Oklahoma City, Oklahoma · NCT07183319

• ALE.P03 alone for adults with advanced CLDN1-positive solid tumors

  This trial tests whether ALE.P03 given alone is safe and can shrink tumors in adults with advanced CLDN1-positive cancers who have already tried standard treatments.

  Recruiting at 41 sites Phase 1/2 Alentis Therapeutics AG · Phoenix, Arizona and 40 other locations · NCT07169734

• Compression stockings to prevent peripheral neuropathy in patients receiving MMAE-containing ADCs for urothelial cancer

  This study will test whether wearing a medical compression stocking on one foot during antibody–drug conjugate (MMAE-containing) infusions can prevent peripheral neuropathy in adults with advanced urothelial carcinoma or other cancers.

  Recruiting Fudan University · Shanghai · NCT07164950

• PF-08046876 for people with advanced solid tumors

  This trial tests a new antibody–drug conjugate called PF-08046876 given by IV in adults with advanced bladder, lung, head and neck, esophageal, or pancreatic cancers to see if it is safe and how it affects tumors.

  Recruiting at 30 sites Phase 1 Pfizer · Duarte, California and 30 other locations · NCT07090499

• Gemcitabine plus carboplatin after progression on enfortumab vedotin and pembrolizumab for advanced urothelial cancer

  This trial tests whether the chemotherapy combination gemcitabine and carboplatin can shrink or control advanced urothelial cancer in people whose cancer got worse after enfortumab vedotin plus pembrolizumab.

  Recruiting at 2 sites Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania and 1 other locations · NCT07043972

• Do women over 50 with sudden bladder infection symptoms and visible blood in their urine need full cancer checks?

  This project will see if women 50 and older who have sudden visible blood in their urine with short-term bladder infection symptoms can safely avoid full cancer investigations.

  Recruiting Vastra Gotaland Region · Uddevalla · NCT07037589

• DR-0202 for advanced, relapsed, or treatment-resistant carcinomas

  This trial tests DR-0202 in adults with advanced or metastatic carcinomas—such as certain breast, lung, cervical, and prostate cancers—that have relapsed or stopped responding to standard treatments.

  Recruiting at 10 sites Phase 1 Dren Bio · Denver, Colorado and 9 other locations · NCT06999187

• Detecting double-positive (tumor marker/CD45+) cells in the blood of people with metastatic cancer

  This one-day study will test two blood-based methods to find double-positive tumor/CD45+ circulating cells in adults who are about to start treatment for various metastatic cancers.

  Recruiting Institut Claudius Regaud · Toulouse · NCT06967961

• DCC-2812 in advanced kidney, bladder, and castration-resistant prostate cancers

  This trial will test whether the oral drug DCC-2812 is safe and shows early signs of benefit for people with advanced kidney (renal cell), bladder (urothelial), or castration-resistant prostate cancer.

  Recruiting at 8 sites Phase 1 Deciphera Pharmaceuticals, LLC · Boston, Massachusetts and 7 other locations · NCT06966024

• Evaluating MT-4561 in Patients with Advanced Solid Tumors

  This study is testing a new drug called MT-4561 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 6 sites Phase 1/2 Tanabe Pharma America, Inc. · Los Angeles, California and 5 other locations · NCT06943521

• Comparing two treatments for advanced urothelial carcinoma

  This study is testing if a combination of two treatments can help people with advanced bladder cancer do better than using just one of the treatments alone.

  Recruiting at 2 sites Phase 2 Mabwell (Shanghai) Bioscience Co., Ltd. · Changsha, Hunan and 1 other locations · NCT06823427

• UGN-104 treatment for low-grade upper tract urothelial cancer

  This Phase 3 trial tests whether weekly UGN-104 instillations can clear low-grade upper tract urothelial cancer in patients with small papillary tumors in the renal pelvis.

  Recruiting at 72 sites Phase 3 UroGen Pharma Ltd. · Homewood, Alabama and 78 other locations · NCT06774131

• Evaluating zanidatamab for HER2-expressing tumors

  This study is testing a new drug called zanidatamab to see if it can help people with certain types of cancer that have high levels of HER2 and who have already tried other treatments without success.

  Recruiting at 30 sites Phase 2 Jazz Pharmaceuticals · Prescott, Arizona and 41 other locations · NCT06695845

• Using Ivocizumab to treat various advanced rare tumors

  This study is testing if a new treatment called Ivocizumab can help people with different types of advanced rare tumors feel better and live longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06683846

• Combination therapy for high-risk muscle-invasive bladder cancer

  This study is testing if a combination of two cancer drugs can help people with high-risk bladder cancer stay cancer-free after surgery.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06682728

• Evaluating ABSK061 and ABSK043 for treating advanced solid tumors

  This study is testing a new combination of two drugs to see if they can help people with advanced solid tumors that have specific genetic changes.

  Recruiting Phase 2 Abbisko Therapeutics Co, Ltd · Guiyang, Guizhou and 20 other locations · NCT06632262

• Combination of 9MW2821 and Toripalimab for advanced bladder cancer

  This study is testing if a new combination of two drugs, 9MW2821 and Toripalimab, can help people with advanced bladder cancer do better than the usual chemotherapy.

  Recruiting Phase 3 Mabwell (Shanghai) Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT06592326

• Investigating QXL138AM for patients with advanced solid tumors and multiple myeloma

  This study is testing a new drug called QXL138AM to see if it can safely help people with advanced solid tumors and multiple myeloma.

  Recruiting at 11 sites Phase 1 Nammi Therapeutics Inc · Los Angeles, California and 10 other locations · NCT06582017

• Testing ZM008 alone and with Pembrolizumab in patients with advanced solid tumors

  This study is testing a new treatment called ZM008, alone and with another drug called Pembrolizumab, to see if it can help patients with advanced solid tumors who have run out of other treatment options.

  Recruiting at 3 sites Phase 1 Zumutor Biologics Inc. · Boston, Massachusetts and 2 other locations · NCT06451497

• Combination therapy for advanced bladder cancer

  This study is testing a new combination treatment for people with advanced bladder cancer to see if it helps them feel better and stay safe.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06405425

• Improving tumor detection before bladder cancer surgery

  This study is testing a new combination of tests to see if they can accurately find leftover tumors in bladder cancer patients before they have surgery.

  Recruiting at 2 sites Fox Chase Cancer Center · Omaha, Nebraska and 1 other locations · NCT06396533

• Neoadjuvant enfortumab vedotin plus pembrolizumab for cisplatin-eligible upper tract urothelial cancer

  This trial tests whether giving enfortumab vedotin with pembrolizumab before surgery helps people with high-grade, cisplatin-eligible upper tract urothelial cancer.

  Recruiting at 2 sites Phase 2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan and 1 other locations · NCT06356155

• Evaluating LB-LR1109 for treating solid tumors

  This study is testing a new treatment called LB-LR1109 to see how safe it is and how well it works for people with advanced solid tumors that can't be treated with standard options.

  Recruiting Phase 1 LG Chem · Fairfax, Virginia · NCT06332755

• Validation of urine DNA testing for diagnosing urothelial cancer

  This study is testing whether a new urine test for cancer can help people suspected of having urothelial cancer avoid unnecessary procedures like cystoscopy.

  Recruiting at 7 sites Tampere University Hospital · Chicago, Illinois and 7 other locations · NCT06310759

• Evaluating BL-M07D1 for HER2 Expressing Solid Tumors

  This study is testing a new treatment called BL-M07D1 to see if it is safe and effective for people with advanced solid tumors that have a specific protein called HER2 after they have tried other treatments.

  Recruiting at 24 sites Phase 1 SystImmune Inc. · Birmingham, Alabama and 25 other locations · NCT06293898

• Comparing home and clinic administration of nivolumab for cancer treatment

  This study tests whether giving cancer patients their treatment at home instead of in a clinic makes them feel better and prefer their care more.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT06265285

• Surgery for Upper Tract Urothelial Carcinoma with or without Lymph Node Removal

  This study is testing whether removing lymph nodes during surgery helps people with upper tract urothelial carcinoma live longer and have fewer cancer recurrences compared to those who don’t have the lymph nodes removed.

  Recruiting at 4 sites Case Comprehensive Cancer Center · Gainesville, Florida and 3 other locations · NCT06262516

• Screening for bladder cancer in people with Lynch syndrome using urine tests

  This study is testing a new urine test to see if it can better find bladder cancer early in people with Lynch syndrome compared to the usual methods.

  Recruiting at 2 sites Tampere University Hospital · Vancouver and 1 other locations · NCT06218433

• Understanding treatment for older patients with advanced bladder cancer

  This study is testing a new way to help older patients with advanced bladder cancer who can't take certain chemotherapy drugs by using a survey to see how well treatments work and how they affect their quality of life.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06138561

• Comparing radioimmunotherapy and chemotherapy for high-risk urothelial carcinoma

  This study is testing whether a new treatment that combines radiation and immune therapy works better than traditional chemotherapy for patients with high-risk bladder cancer after surgery.

  Recruiting at 3 sites Peking University First Hospital · Beijing and 2 other locations · NCT06120374

• Analyzing blood samples for bladder cancer biomarkers

  This study is testing whether analyzing blood samples can help find important markers for bladder cancer in patients with early-stage disease to improve their treatment and quality of life.

  Recruiting IRCCS San Raffaele · Milan · NCT06116396

• Combining local therapies with systemic treatment for certain cancers

  This study is testing if adding local treatments like targeted radiation or ablation can help people with certain types of cancer, such as prostate or kidney cancer, stay on their main treatment longer without needing changes.

  Recruiting University of California, Davis · Sacramento, California · NCT06101290

• Testing NEO212 for treating certain brain tumors and metastases

  This study is testing a new treatment called NEO212 for people with certain types of brain tumors to see if it is safe and effective when combined with standard treatments.

  Recruiting at 8 sites Phase 1/2 Neonc Technologies, Inc. · Beverly Hills, California and 7 other locations · NCT06047379

• Home-based exercise program to improve physical function for bladder cancer patients

  This study is testing whether a home-based exercise program can help bladder cancer patients recover better and improve their physical health before and after surgery.

  Recruiting University of Washington · Seattle, Washington · NCT06040762

• Reducing invasive tests for patients with blood in urine

  This study is testing a new urine test to see if it can help people with blood in their urine avoid unnecessary invasive procedures while still checking for serious conditions like bladder cancer.

  Recruiting Erasmus Medical Center · Rotterdam · NCT06026189

• Testing new treatments for advanced bladder cancer and other solid tumors

  This study is testing two new treatments for people with advanced bladder cancer and other solid tumors who have not had success with standard therapies or can't handle them.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT05965856

• Registry of patients with upper tract urothelial cancer treated with Jelmyto

  This study is looking at how well Jelmyto works for people with upper tract urothelial cancer by tracking their experiences and outcomes over time.

  Recruiting at 22 sites UroGen Pharma Ltd. · Santa Monica, California and 21 other locations · NCT05874921

• Screening for bladder cancer using urine tests

  This study is testing if regular urine tests every six months can help catch bladder cancer earlier in people over 50 who are at high risk.

  Recruiting University of Texas Southwestern Medical Center · Dallas, Texas · NCT05646485

• Chemotherapy followed by immunotherapy for advanced bladder cancer

  This study is testing if giving chemotherapy followed by an immunotherapy called avelumab can help people with advanced bladder cancer before they have surgery to remove the tumor.

  Recruiting at 4 sites Phase 2 Erasmus Medical Center · Nijmegen, Gelderland and 3 other locations · NCT05600127

• Imaging Nectin-4 in Bladder Cancer

  This study is testing a new imaging method to see if it can help find a specific protein in patients with advanced bladder cancer to improve diagnosis and treatment planning.

  Recruiting Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT05321316

• Combination treatment for advanced urothelial carcinoma

  This study is testing a new combination treatment for advanced bladder cancer to see if it works better than chemotherapy alone for patients who haven't received treatment before.

  Recruiting at 2 sites Phase 3 RemeGen Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT05302284

• Analysis of pembrolizumab and enfortumab vedotin in urothelial carcinoma patients

  This study is testing how well the treatments pembrolizumab and enfortumab vedotin work for patients with urothelial carcinoma who can't take platinum-based chemotherapy or have not improved after it.

  Recruiting Hospital of Macerata · Province of Macerata, Macerata · NCT05290038

• Evaluating GI-101 with Pembrolizumab, Lenvatinib, or Radiotherapy in Advanced Solid Tumors

  This study is testing a new treatment called GI-101, alone and with other therapies, to see if it can help people with advanced solid tumors.

  Recruiting at 13 sites Phase 1/2 GI Innovation, Inc. · New York, New York and 12 other locations · NCT04977453

• Collection of samples from patients with bladder cancer

  This study is collecting samples from bladder cancer patients to see how the bladder's bacteria might affect their treatment outcomes with BCG immunotherapy and chemotherapy.

  Recruiting University Hospital, Toulouse · Toulouse · NCT04970472

• Testing BMS-986340 alone and with other treatments for advanced solid tumors

  This study is testing a new treatment called BMS-986340, both on its own and with other drugs, to see how safe it is for people with advanced solid tumors.

  Recruiting at 39 sites Phase 1/2 Bristol-Myers Squibb · Clovis, California and 46 other locations · NCT04895709

• Combining immune checkpoint inhibitors with radiotherapy for cancer treatment

  This study is testing if combining immune checkpoint inhibitors with radiotherapy can improve treatment for patients with certain types of cancer, like head and neck and lung cancer.

  Recruiting University of Erlangen-Nürnberg Medical School · Erlangen, Bavaria · NCT04892849

• Treatment of HER2 expressing urothelial cancer with disitamab vedotin and pembrolizumab

  This study is testing if a new drug called disitamab vedotin, alone or with another drug called pembrolizumab, can help shrink tumors in patients with a specific type of bladder cancer that can't be surgically removed.

  Recruiting at 169 sites Phase 2 Seagen Inc. · Gilbert, Arizona and 220 other locations · NCT04879329

• Combination of Talazoparib and Avelumab for Urothelial Carcinoma Maintenance Therapy

  This study is testing if a combination of two drugs, Talazoparib and Avelumab, can help people with advanced bladder cancer stay healthy longer after their initial chemotherapy.

  Recruiting at 11 sites Phase 2 Centre Francois Baclesse · Angers and 13 other locations · NCT04678362

• Understanding how kidney tumors use nutrients for growth

  This study tests how kidney tumors use certain nutrients to grow by giving participants a special nutrient infusion during surgery and checking their blood and tissue samples.

  Recruiting University of Texas Southwestern Medical Center · Dallas, Texas · NCT04623502

• Collection of tumor samples from cancer patients for diagnostic test development

  This study is collecting tumor samples from cancer patients who are getting certain treatments to help create better tests for managing cancer in the future.

  Recruiting Cofactor Genomics, Inc. · San Francisco, California · NCT04510129

• Testing a new treatment for advanced solid tumors with pembrolizumab

  This study is testing a new treatment using INBRX-106 alone and with pembrolizumab to see if it can help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting at 17 sites Phase 1/2 Inhibrx Biosciences, Inc · Duarte, California and 59 other locations · NCT04198766

• AI-based precision oncology clinical trial matching and registry

  This study is testing whether an AI tool can help match cancer patients with the right clinical trials based on their specific cancer details to see if it improves their chances of getting into trials and their overall outcomes.

  Recruiting at 68 sites Massive Bio, Inc. · Birmingham, Alabama and 67 other locations · NCT03452774

• National registry for patients with advanced kidney and bladder cancer

  This study is setting up a national registry to track the experiences and treatments of patients with advanced kidney and bladder cancer over a few years to help improve care and research in the future.

  Recruiting iOMEDICO AG · Multiple Locations · NCT03374267

NIH-funded research (16)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Understanding bladder cancer biology to find new biomarkers and therapies

  A study at Tuskegee University will look at the molecules inside high-grade bladder cancer to discover new markers and potential treatment targets.

  NIH research Tuskegee University · Tuskegee Institute, United States · NIH-11621784

• Improved 3D guidance for kidney-sparing endoscopic UTUC treatment

  A Vanderbilt team is testing a new 3D-guided approach to precisely locate and treat upper tract urothelial cancer during kidney-sparing endoscopic procedures.

  NIH research Vanderbilt University Medical Center · Nashville, United States · NIH-11366209

• Immune cells in bladder cancer: predicting who benefits from stronger pre-surgery therapy

  This grant aims to find immune clues in muscle-invasive bladder cancer to identify which patients will best respond to intensified pre-surgery treatment.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11357654

• Synergistic immune boost for bladder cancer with EphrinB2 blocker and PD-1 therapy

  A phase II trial tests whether a new EphrinB2 blocker (sEphB4-HSA) plus pembrolizumab can help patients with muscle-invasive bladder cancer who have EphrinB2 and low Nectin4 to fight their cancer.

  NIH research University of Southern California · Los Angeles, UNITED STATES · NIH-11335673

• HER2 PET scans to find HER2 differences and predict response to HER2-targeted therapy in bladder cancer

  This project uses a PET scan that lights up HER2 to help show which people with metastatic bladder (urothelial) cancer might benefit from HER2-targeted antibody-drug conjugates.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11304514

• Treating bladder cancer with ARID1A gene changes

  This project will develop new treatment approaches for people with bladder cancer whose tumors have changes in the ARID1A gene.

  NIH research VA Salt Lake City Healthcare System · Salt Lake City, United States · NIH-11213965

• IL-12 bladder immune therapy for dogs with invasive bladder cancer

  This project gives a sticky IL-12 immune medicine directly into the bladder of pet dogs with invasive bladder cancer to shrink tumors and stimulate immune responses.

  NIH research North Carolina State University Raleigh · Raleigh, United States · NIH-11163282

• Combining EphrinB2 inhibition with PD-1 therapy for bladder cancer treatment.

  This study is testing a new treatment for muscle invasive bladder cancer that combines two therapies to see if it helps patients who usually don’t respond well to current options, focusing on those with specific levels of certain proteins in their tumors.

  NIH research University of Southern California · Los Angeles, UNITED STATES · NIH-11134306

• Using HER2 PET imaging to improve treatment for bladder cancer

  This study is looking at how a special imaging technique can help doctors see differences in a protein called HER2 in bladder cancer, which might help them figure out the best treatments for patients.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11061006

• Identifying DNA changes to improve diagnosis and prognosis of upper tract urothelial carcinoma

  This study is looking at how changes in DNA from urine samples can help doctors better diagnose and understand the risks of upper tract urothelial carcinoma (UTUC) before surgery, making it easier for patients to get the right treatment.

  NIH research University of Southern California · Los Angeles, UNITED STATES · NIH-11044045

• Targeting mutations in bladder cancer related to the ARID1A gene

  This study is looking at how changes in the ARID1A gene might affect bladder cancer in older Veterans, especially those who have been exposed to things like smoking, to help find better treatments for those with this gene mutation.

  NIH research VA Salt Lake City Healthcare System · Salt Lake City, United States · NIH-10951535

• Using immunotherapy to treat bladder cancer in dogs

  This study is testing a new treatment for dogs with invasive bladder cancer that involves giving a special medicine directly into their bladder, and it's designed to see how safe and effective it is for helping our furry friends feel better.

  NIH research North Carolina State University Raleigh · Raleigh, United States · NIH-10920439

• Understanding how specific gene dysfunction affects bladder cancer

  This study is looking at how certain gene changes might affect the development of bladder cancer, and it aims to find out more about these changes using special mouse models, which could help improve diagnosis and treatment for people with this type of cancer.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-10894874

• Understanding immune cells in bladder cancer treatment

  This study is looking at how the immune cells in bladder cancer respond to chemotherapy before surgery, to help find out which patients might do better with stronger treatments.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-10880631

• Testing new immunotherapy for bladder cancer that comes back after treatment

  This study is looking at a new way to help people with bladder cancer that has come back after regular treatment, by combining immunotherapy with BCG and radiation to see if it works better, while also checking how safe it is and using genetic information to help decide on the best treatment for each patient.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-10861714

• Investigating how certain enzymes affect bladder cancer mutations

  This study is looking at how two specific enzymes might cause changes in bladder cancer, which could help explain why some tumors grow faster and resist treatment, and it's designed for people interested in understanding more about their cancer and potential therapies.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-10825932

Related topics

Quick answers

How many Urothelial Carcinoma clinical trials are recruiting right now?

70, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 29 countries. The most sites are in United States (42 trials), China (17 trials), Spain (8 trials), Japan (6 trials), Canada (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 20, Phase 1: 12, Phase 1/2: 7, Phase 3: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →